Handelsbanken Fonder AB - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 169 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.

Quarter-by-quarter ownership
Handelsbanken Fonder AB ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q1 2023$209
-19.3%
5,8000.0%0.00%
-50.0%
Q4 2022$259
-99.9%
5,800
-34.8%
0.00%0.0%
Q3 2022$250,000
+4.2%
8,9000.0%0.00%0.0%
Q2 2022$240,000
-20.8%
8,9000.0%0.00%0.0%
Q1 2022$303,000
-11.9%
8,9000.0%0.00%0.0%
Q4 2021$344,0008,9000.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2022
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 1,017,524$20,961,0007.56%
Octagon Capital Advisors LP 561,398$11,565,0004.36%
COMMODORE CAPITAL LP 369,951$7,621,0003.04%
Opaleye Management Inc. 985,000$20,291,0002.98%
VR Adviser, LLC 1,240,610$25,557,0002.77%
TSP Capital Management Group, LLC 359,229$7,400,0002.61%
RTW INVESTMENTS, LP 3,908,947$80,524,0001.26%
Ghost Tree Capital, LLC 250,000$5,150,0001.21%
Tri Locum Partners LP 196,672$4,051,0001.00%
Redmile Group, LLC 3,387,788$69,788,0000.98%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders